Investigating a new approach to manage pain in oral cancer patients
Targeting HB-EGF and trigeminal EGFR for oral cancer pain and opioid tolerance
This study is looking at how a protein called HB-EGF influences pain and how well opioids work for people with oral cancer, and it aims to help improve pain management for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10582847 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, HB-EGF, affects pain and opioid tolerance in patients with oral cancer. The team will explore the role of the epidermal growth factor receptor (EGFR) in pain management by examining its interaction with opioid receptors and other proteins involved in pain signaling. Through a combination of pharmacological and genetic methods, they aim to identify how these mechanisms contribute to pain and tolerance to opioid medications. Patients may be involved in assessments that measure pain-related behaviors and responses to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from oral cancer who experience severe pain and are currently using opioids for pain management.
Not a fit: Patients who do not have oral cancer or those who do not experience significant pain may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively manage pain in oral cancer patients without the rapid development of opioid tolerance.
How similar studies have performed: While the specific approach of targeting HB-EGF in oral cancer pain is novel, similar research has shown promise in understanding pain mechanisms and developing new pain management strategies.
Where this research is happening
New York, United States
- New York University — New York, United States (Active)
Researchers
- Principal investigator: Ye, Yi — New York University
- Study coordinator: Ye, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.